Acknowledgements

1/2/02


Click here to start


Table of Contents

PPT Slide

Acknowledgements

Cervical Cancer Global Perspective

Cervical Cancer U.S.A. Perspective

Precursor Lesions of Cervical Carcinoma

PPT Slide

Cervical Lesions: “Pyramid” of Findings (U.S.)*

Natural History of CIN

Natural History of CIN

Natural History of Cervical Dysplasiaa

HPV Vaccine Composition

Squamous Cell Carcinoma* - HPV 16 Most Common Type

Adenocarcinoma (Cervix) - HPV 18 - Most Common Type

Incidence of Squamous Cell Carcinoma (SCC) vs. Adenocarcinoma (ADC) of the Cervix

Risk of CIN 2 or 3: Relation to HPV Type 16 and 18

Risk of CIN 2 or 3: Relation to HPV Type 16

PPT Slide

“Theoretical” Endpoints - HPV Preventive Vaccines

Possible Endpoints – HPV Vaccines

Possible Endpoints – HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Possible Endpoints - HPV Vaccines

Efficacy Trial Analysis

Accelerated Approval (AA)

Accelerated Approval (AA)

Accelerated Approval (AA)

FDA Questions

FDA Questions (continued)

Author: CBER